In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares. Sentiment for ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.Sentiment for Life Sciences and Diagnostic Tools and Contract ...

Myriad Genetics has a 12-month low of $7.35 and a 12-month high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

The "Genetic Screening Testing for Reproductive Health Market - A Global and Regional Analysis: Focus on Test Type, Application, Technology, End User, and Country-Level Analysis - Analysis and ...

While current treatments are largely guided by the genetic makeup of a patient's tumor, this research suggests that looking at a patient's inherited DNA could further refine diagnosis, risk ...

In RuneScape Dragonwilds, survival hinges on mastering diverse skills. Players can immediately mine, chop wood, and cook, unlocking powerful abilities as they level up. The game features skill ...

Mary Annette PemberICTThe sight of a room full of human cadavers can be off-putting for some, but not for Haley Omeasoo.In ...

New research has revealed that Schistosoma haematobium (S. haematobium), a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with ...